{"id":"NCT02282527","sponsor":"Grifols Therapeutics LLC","briefTitle":"A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency","officialTitle":"A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha₁-Proteinase Inhibitor (Human) Compared to Prolastin®-C in Subjects With Alpha₁-Antitrypsin Deficiency","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-10","primaryCompletion":"2016-01","completion":"2016-01","firstPosted":"2014-11-04","resultsPosted":"2017-03-13","lastUpdate":"2017-03-13"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alpha₁-Antitrypsin Deficiency"],"interventions":[{"type":"BIOLOGICAL","name":"Liquid Alpha₁-PI","otherNames":[]},{"type":"BIOLOGICAL","name":"Prolastin-C","otherNames":[]}],"arms":[{"label":"Treatment Sequence 1","type":"OTHER"},{"label":"Treatment Sequence 2","type":"OTHER"}],"summary":"Grifols Therapeutics Inc. conducted a multi-center, randomized, double-blind, crossover study to evaluate the safety, immunogenicity, and pharmacokinetics (PK) of Liquid Alpha₁-PI compared to the currently licensed product, Prolastin-C, in subjects with Alpha₁-Antitrypsin Deficiency (AATD).","primaryOutcome":{"measure":"AUC(0-7 Days) Based on Antigenic Content","timeFrame":"pre-dose, 0, 15 min, 30 min, 1 hour, 2 hours, 4 hours, 8 hours, 1 day, 2 days, 5 days, 7 days post dose","effectByArm":[{"arm":"Liquid Alpha₁-PI","deltaMin":203.2,"sd":23.041},{"arm":"Prolastin-C","deltaMin":198.38,"sd":25.23}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":32},"commonTop":["Nasopharyngitis","Diarrhoea","Fatigue","Pyrexia","Dermatitis Contact"]}}